Exchange: NASDAQ·Updated 04:10 PM EST
FULC logo

FULC Fulcrum Therapeutics Inc

$3.69
$0.02
(0.54%)
Today
Closed $3.69
$0.00
(0.00%)
After Hours
EarningsFeb 24
Mkt Cap$283.38M
Vol2.16M

About FULC

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.
50

Neutral Sentiment

How do you feel about FULC?

StocktwitsEarnings
$FULC Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.14 up 54.84% YoY • Fulcrum Therapeutics expects the Merger to close in fourth quarter 2026 and expects to declare a $275M aggregate cash dividend to pre-Merger stockholders, subject to adjustment under the Merger Agreement.

Advertisement|Remove ads.